The cost of teaching an intern in New South Wales

To the Editor: While Oates and colleagues1 provide an insightful introduction to intern teaching in New South Wales, I offer an alternative to their views; what is considered teaching is not agreed on, and does not necessarily translate to learning.

Informal teaching (and learning) occurs during work-based activities like ward rounds, departmental meetings, grand rounds and quality improvement activities. These are set out as learning opportunities for interns by the Australian Medical Council.2

What supervisors consider to be informal learning probably does not coincide with interns’ expectations of teaching.

Junior medical officers should realise that, for them, learning from informal teaching is not about acquiring knowledge of diseases or skills, as it is for medical students. Rather, it is about acquiring knowledge of work processes and resource management — expertise not well described in medical literature. Fiona Lake, a developer of Teaching on the Run, bases her own teaching on the idea that if something can be learnt from a textbook, it is of no help for her to teach it as well. “It’s a complete waste of time for me to teach it!”3

Adult learning forms a significant portion of any postgraduate vocational training and can occur by both a cognitive approach, based on andragogy theory, and an apprenticeship model, in which “learning by doing” and “master as role model” are the basis.4

Perhaps the main issue is not the perception of how teaching should be done, but how learning should occur.

Shyan LL Goh Orthopaedic Surgeon Rockhampton Hospital, Rockhampton, QLD.
sgh@hotmail.com

Competing interests: No relevant disclosures.

doi: 10.5694/mja14.00550


IN REPLY: We fully agree with Goh that teaching does not translate to learning. In our article,1 we were careful to concentrate on teaching, both formal and informal, received by interns, and not learning — something that is much more difficult to measure.

We defined informal teaching as being spontaneous, non–timetabled and sporadic, pointing out that it may occur during a ward round, walking along a corridor or at the end of a consultation.

Like Goh, we acknowledged that teaching also occurs as a result of observation and practical experience, which were not included in our study. We emphasised that there is much more involved in intern education than the formal and informal teaching considered here, and we mentioned: observation by interns; self-learning; practical experience; self-reflection; and the influence of role models.

It may well be that some teaching occurred that was not identified as such by the interns surveyed. What is important is that formal and informal teaching should be acknowledged as a crucial part of the intern experience and that supervisors ensure that teaching and learning, in all its forms, is emphasised.

R Kim Oates Emeritus Professor
Kerry J Goulston Emeritus Professor
Sydney Medical School, University of Sydney, Sydney, NSW.
kim.oates@sydney.edu.au

Competing interests: No relevant disclosures.

Preventing peripheral intravenous catheter-associated bloodstream infection: the randomised controlled trial versus the real world

To the Editor: Debate regarding the prevention of peripheral intravenous catheter (PIVC)-associated bloodstream infection has been enriched by research and letters published in the Journal.1-3,4 Stuart and colleagues and Collignon and colleagues highlighted an association of long dwell times with PIVC-associated bloodstream infection.1,2 Rickard and colleagues refer to contrasting high-level evidence in a Cochrane review.1-3 We would suggest that important lessons can be learnt from both perspectives.

The Hawthorne effect and strict inclusion and exclusion criteria mean that, while largely free of bias, the outcomes of clinical trials are not generalisable. The retrospective data on PIVC-associated bloodstream infections reported by Stuart et al and Collignon et al, while methodologically limited, demonstrate the real-world experience of hundreds of patients.1,2

We believe that clinicians should consider all forms of evidence when designing processes to ensure safe stewardship of PIVCs. In health services with independent “line teams” and a comprehensive PIVC insertion bundle, a “replace as clinically indicated” approach may be appropriate. Other health care services may be better suited to a mandatory replacement policy.

Given evidence that half of PIVCs inserted in our tertiary emergency department (ED) were unused,4 along with the evidence of PIVC-associated infection,1 Monash Health introduced a comprehensive multimodal change process to reduce unused PIVCs and...
subsequent bloodstream infections. Clinicians in Monash Health EDs are asked to only insert a PIVC if they feel it is at least 80% likely it will be used in the following 4 hours. An accompanying education campaign provides guidance in cases where a precautionary PIVC may be required, such as for patients who present after a seizure. The aim of the intervention is to avoid insertion of unnecessary PIVCs, while ensuring appropriate insertion, and to improve insertion methods. Four months after the intervention began, we demonstrated a reduction in total monthly PIVCs from 1413 to 928 and an unused PIVC rate of 19.3% (unpublished data). This change process has been offered to EDs throughout Victoria by the Department of Health.

We would support the establishment of a specific national standard regarding the stewardship of PIVCs, which should include the need to carefully evaluate whether insertion of the PIVC is necessary.

Diana Egerton-Warburton Director of Emergency Medicine Research1 and Adjunct Senior Lecturer2

George Braitberg Professor of Emergency Medicine3

Anthony Kambourakis Director of Emergency Medicine1

1 Monash Health, Melbourne, VIC.
2 Southern Clinical School, Monash University, Melbourne, VIC.
3 Department of Health, Victoria.

diana.egertonwarburton@monashhealth.org

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00363

---

Ipilimumab-induced hypophysitis: early Australian experience

TO THE EDITOR: We report two men aged in their 60s receiving ipilimumab for metastatic melanoma who presented with headache and constitutional symptoms after the third 3-weekly dose, and were diagnosed with ipilimumab-induced hypophysitis. Ipilimumab is a monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen 4, resulting in T-cell activation and proliferation. It was the first therapy to yield a survival benefit in metastatic melanoma,1 but at the cost of frequent immune-related adverse events.2

Patient 1 experienced headache, fatigue, postural lightheadedness, anorexia and asthenia. Morning blood test results before steroid administration were consistent with central hypocortisolism (serum cortisol, < 28 nmol/L [reference interval (RI), 70–650 nmol/mL]; inappropriately normal adrenocorticotropic hormone [ACTH], 1.2 pmol/L [RI, 0–12.0 pmol/mL]; hypothryphidism (low thyroid-stimulating hormone [TSH], 0.2 mIU/L [RI, 0.4–4.0 mIU/L]; low free thyroxine [FT4], 9.9 pmol/L [RI, 9.0–19.0 pmol/mL]; normal free triiodothyronine [FT3], 4.7 pmol/L [RI, 2.6–6.0 pmol/mL]), and hypogonadism (low testosterone, 2.8 pmol/L [9.5–28.0 nmol/mL]; insufficiently raised follicle-stimulating hormone [FSH], 14.0 IU/L [RI, 1.0–12.0 IU/L]; luteinising hormone [LH] within RI, 3.7 IU/L [RI, 0.6–12 IU/L]). Insulin-like growth factor-1, growth hormone and prolactin levels were within RIs.

Patient 2 presented with severe headaches and emesis. Morning blood test results demonstrated central hypothyroidism (low TSH, 0.24 mIU/L [RI, 0.27–4.20 mIU/L]; FT4, 11.4 pmol/L [RI, 12.0–22.0 pmol/L]; and FT3, 2.8 pmol/L [RI, 3.0–7.8 pmol/L]) and hypogonadism (low testosterone [2.1 nmol/L] and inappropriately normal FSH [8.1 IU/L] and LH [3.9 IU/L]). Although morning cortisol and ACTH levels were initially adequate, the patient had been placed on high-dose dexamethasone because of suspicion of brain metastases, which were later excluded by lumbar puncture and brain MRI. The pituitary was not enlarged, but superior convexity was evident.

Both patients received a 3-week tapering course of prednisolone starting at 30 mg daily and weaned to replacement doses. They received thyroxine and, later, testosterone replacement. Ipilimumab was continued to include the standard fourth and final dose. The endocrine abnormalities persisted in both men at 3–6-month follow-up, despite normalisation of MRI findings (Box). For Patient 2, a subsequent insulin-tolerance test demonstrated a flat cortisol response consistent with corticotropic insufficiency due to hypophysitis, although suppression from exogenous steroids may have contributed. Both patients experienced tumour progression over the follow-up period.

Ipilimumab was registered by the Therapeutic Goods Administration in 2011 and funded by the Pharmaceutical Benefits Scheme from August 2013. These are the second Australian cases of ipilimumab-induced hypophysitis to be published in the Journal.3 Ipilimumab-induced thyroiditis and adenalin is are common differential diagnoses to consider.4 Suprascellar extension is seen frequently, requiring urgent ophthalmic evaluation. There are no prospective data on whether high-dose steroids improve...

---

Interdisciplinary awareness is required to ensure that replacement glucocorticoids are started promptly on diagnosis

De Sousa et al
pituitary recovery or abrogate the tumour response to ipilimumab. Our cases demonstrated no short-term advantage. Interdisciplinary awareness of this condition is required to ensure that replacement glucocorticoids are started promptly on diagnosis and increased during periods of physiological stress, including surgery or chemotherapy.

Sunita M C De Sousa Pituitary Fellow1
Georgina V Long Associate Professor of Translational Research and Melanoma Biology2
Katherine T Tonks Clinical Research Fellow3
1 Department of Endocrinology, St Vincent’s Hospital, Sydney, NSW. 
2 Melanoma Institute Australia, Sydney, NSW. 
3 Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, NSW.

s.desousa@garvan.org.au

Acknowledgements: We thank Diana Adams of Macarthur Cancer Therapy Centre at Campbelltown Hospital, Sydney, who shared in patient care.

Competing interests: Georgina Long is a consultant adviser to Bristol-Myers Squibb, Merck, Amgen, GlaxoSmithKline, Novartis and Roche.

doi: 10.5694/mja14.00803

Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older

To the Editor: Menzies and colleagues promote the 23-valent polysaccharide pneumococcal vaccine (23vPPV) as effective in people aged 65 years or older.1 I believe their data show exactly the opposite. The vaccine appears to be ineffective. In 2005, a nationally funded vaccination program began with 23vPPV for those aged ≥ 65 years and a 7-valent pneumococcal conjugate vaccine (7vPCV) for children. Subsequently, there was a rapid and dramatic drop in invasive pneumococcal disease in older people, but this was only for disease due to serotypes covered by the childhood 7vPCV. When the effects of the other components of the 23vPPV are examined, there is no fall but instead a statistically significant increase in invasive infections in older people.1

Vaccinating children with highly effective conjugated pneumococcal vaccines is associated with a dramatic decrease in invasive pneumococcal disease not only in children but also in older people. Older people benefit because vaccinated children carry fewer pneumococcal strains and thus pass on fewer invasive strains to parents and grandparents.2-4

I think that the only reasonable conclusion from the study by Menzies et al is that the non-conjugated vaccine is ineffective in those aged ≥ 65 years. Its use may perversely have even been associated with an increase in invasive disease.

This clearly shows the superiority and easily measured benefits of conjugated pneumococcal vaccines

Collignon
of conjugated pneumococcal vaccines. Why persevere with the unconjugated 23vPPV in older people given its poor or potentially non-existent efficacy? We need to ensure that we have effective pneumococcal vaccines available for older people. This means conjugated pneumococcal vaccines.

Peter J Collignon
Professor, Infectious Diseases and Microbiology
Medical School, Australian National University, Canberra, ACT.
Peter.Collignon@act.gov.au

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00272


IN REPLY: We agree with Collignon that pneumococcal conjugate vaccines (PCVs) are superior to polysaccharide pneumococcal vaccines (PPVs), and that the herd immunity impact of the PCV on older people is impressive. However, we do not agree that our study shows that the PPV is ineffective in older people, or that its use has resulted in an increase in disease.

The increases in disease due to serotypes not contained in the 7-valent PCV in the ≧ 65-year age group suggest an underlying increase in adults, probably because of serotype replacement driven by the PCV. The fact that these increases were greater in 50–64-year-olds, in whom PPV use was negligible, suggests an attenuating effect from the PPV. The estimate of effectiveness of the PPV in our study was 61%.

Decisions on the PPV’s continued use in older people will depend on several factors. These include disease rates in older adults due to serotypes covered by the PPV but not the 13-valent PCV, and any likely additional impact of PCV use in adults over and above the herd immunity impacts from PCV use in children.

Robert I Menzies
Deputy Director, Surveillance
Vicki L Krause
Director
Peter B McIntyre
Director
1 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Sydney, NSW.
2 Centre for Disease Control, Department of Health, Darwin, NT.
robert.menzies@health.nsw.gov.au

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00399

Managing information overload

To the Editor: Gee’s introduction to a recent issue of the Journal discussed the impact that the overwhelming growth of health information has on doctors.1 While it is true that doctors are an important mainstay of advice to patients, health librarians are an important resource to doctors. Health librarians are trained to acquire, organise and disseminate credible information resources which enable doctors to find the best evidence to support clinical decision making.2

Perhaps the largest exercise to date on the impact of health libraries has been the 2013 Value of library and information services in patient care study in the United States.3 The study encompassed 56 libraries serving 118 hospitals with a survey of physicians, residents and nurses involved in either patient care or clinical research. There were 16 122 respondents including 5379 physicians, 2123 residents and 6788 nurses. About three-quarters of these respondents reported that they had definitely or probably handled some aspect of patient care differently because of information obtained from libraries. The study found that using health libraries resulted in clinical staff changing the advice given to patients (48%), changing diagnosis (25%) and changing choice of drugs (33%), as well as avoiding or reducing the risk of patients misunderstanding their disease (23%).

Therefore, as Revere and colleagues highlight, it is important to remember that health librarians can...
Global debate around the new post-2015 development goals, which will replace the MDGs when they expire in December 2015, is presently underway, with the intergovernmental Open Working Group on Sustainable Development Goals providing its initial report on the potential goal framework in July 2014 (http://sustainabledevelopment.un.org/focussdgs.html). Although the new goals are not yet finalised, under proposed goal 3 (to ensure healthy lives and promote wellbeing for all at all ages), 13 subgoals are currently being negotiated. The expectation is that the new goals will be universal and applicable to all countries — including high-income nations like Australia — with differentiated targets to redress inequities both between and within countries. Although it is unlikely that there will be any international legal obligation to comply, Australia, as a “good global citizen”, may face significant normative pressures to implement domestic policy changes to reflect post-2015 targets. This raises the question of the likely implications for Australian domestic health policy — and for Indigenous health in particular — in light of the new health and development goals. Through post-2015 commitment to overcome domestic and global health and related inequities, the Australian Government will be more accountable on the world stage not only for its Indigenous peoples but also for all people.

Cindy Shannon
Pro-Vice-Chancellor (Indigenous Education)

Claire E Brolan
Research Fellow, School of Population Health

Deepa Gajjar
Research Officer, School of Population Health
University of Queensland, Brisbane, QLD.

d.gajjar@uq.edu.au

Acknowledgements: This work forms part of Uptake of evidence to policy: the Indigenous Burden of Disease case study — a collaborative 3-year study between the University of Queensland and the University of New South Wales (National Health and Medical Research Council [NHMRC] grant APP1010534) and Go4Health — a research project funded by the European Union Seventh Framework Program (grant HEALTH-F2-2012-305240) and the Australian Government NHMRC-European Union Collaborative Research Grants (grant 1059318).

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00059


Clarification: In “AIDS, loss and renewal” in the 4 August 2014 issue of the Journal (MJA 2014; 201: 130-132), under the heading “No strangers to suffering”, the reference to the murder of Dwayne Jones requires clarification. This section should begin: So we think of them and of others who have suffered, or are suffering, through irrational, unjust and destructive acts:

- Of Dwayne Jones, murdered in Montego Bay, Jamaica, in July 2013 when she identified as a woman. She was beaten, stabbed, shot and then run over by a car and dumped in a ditch. No one brought to justice.